PriceTargets.com logo

CONMED - CNMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $112.00
  • Forecasted Upside: 18.38%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$94.61 As of 03/24/2023 12:12 PM ET
▼ -1.77 (-1.84%)

This chart shows the closing price for CNMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CONMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNMD

Analyst Price Target is $112.00
▲ +18.38% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CONMED in the last 3 months. The average price target is $112.00, with a high forecast of $122.00 and a low forecast of $96.00. The average price target represents a 18.38% upside from the last price of $94.61.

This chart shows the closing price for CNMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in CONMED.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$96.00Low
2/3/2023Needham & Company LLCBoost TargetBuy$106.00 ➝ $122.00Low
2/3/2023Piper SandlerBoost TargetOverweight$108.00 ➝ $118.00Low
11/15/2022Needham & Company LLCBoost TargetBuy$90.00 ➝ $106.00Low
(Data available from 3/24/2018 forward)

News Sentiment Rating

0.88 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/24/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
2/22/2023
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2023

Current Sentiment

  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

CONMED logo
CONMED Corp. operates as a medical technology company, which engages in the development, manufacturing, and sale of surgical devices and related equipment. It operates through the United States, Europe, Middle East, and Africa, and Asia Pacific geographical segments. Its products are used by surgeons and physicians in a variety of medical specialties, including orthopedic surgery, general surgery, gynecology, neurosurgery, thoracic surgery, and gastroenterology. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.
Read More

Today's Range

Now: $94.61
Low: $94.04
High: $96.04

50 Day Range

MA: $96.68
Low: $90.22
High: $107.27

52 Week Range

Now: $94.61
Low: $71.09
High: $155.51

Volume

85,596 shs

Average Volume

402,740 shs

Market Capitalization

$2.89 billion

P/E Ratio

N/A

Dividend Yield

0.87%

Beta

1.35

Frequently Asked Questions

What sell-side analysts currently cover shares of CONMED?

The following Wall Street sell-side analysts have issued research reports on CONMED in the last twelve months: Needham & Company LLC, Piper Sandler, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for CNMD.

What is the current price target for CONMED?

3 Wall Street analysts have set twelve-month price targets for CONMED in the last year. Their average twelve-month price target is $112.00, suggesting a possible upside of 18.4%. Needham & Company LLC has the highest price target set, predicting CNMD will reach $122.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $96.00 for CONMED in the next year.
View the latest price targets for CNMD.

What is the current consensus analyst rating for CONMED?

CONMED currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNMD will outperform the market and that investors should add to their positions of CONMED.
View the latest ratings for CNMD.

What other companies compete with CONMED?

Other companies that are similar to CONMED include InMode, Integer, TransMedics Group, LivaNova and Outset Medical. Learn More about companies similar to CONMED.

How do I contact CONMED's investor relations team?

CONMED's physical mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company's listed phone number is (727) 392-6464. The official website for CONMED is www.conmed.com. Learn More about contacing CONMED investor relations.